|
|
|
|
|
|||||||
|
Session 92
Poster Session
Switch Studies/Treatment of Lipodystrophy Syndromes 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 699-T. | A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) C. Fisac*, E. Fumero, M. Crespo, B. Rosón, N. Virgili, E. Ribera, E. Ferrer, J. M. Gatell, and D. Podzamczer Hosp. Bellvitge, Hosp. Vall d`Hebron, Hosp. Clin., Barcelona, Spain
| ||
| 700-T. | A Randomised, Controlled, Open-Label Study of Revision of Antiretroviral Regimens Containing Stavudine (d4T) and/or a Protease Inhibitor (PI) to Zidovudine (ZDV)/Lamivudine (3TC)/Abacavir (ABC) to Prevent or Reverse Lipoatrophy: 48-Week Data M. John*1, I. James1, E. McKinnon1, D. Nolan1, S. Herrmann1, A. Cain1, O. P. Martinez1, A. White2, and S. Mallal1 1Royal Perth Hosp. and Murdoch Univ., Perth, Australia and 2GlaxoSmithKline, Greenford, UK
| ||
| 701-T. | Improvements in Lipoatrophy (LA) Are Observed after 24 Weeks when Stavudine (d4T) Is Replaced by Either Abacavir (ABC) or Zidovudine (ZDV) G. McComsey*1, T. Lonergan2, R. Fisher3, M. Sension4, C. Hoppel1,5, V. Williams3, L. Ross3, and J. Hernandez3 1Case Western Reserve, Cleveland, OH; 2Univ. of California, San Diego; 3GlaxoSmithKline, Res. Triangle Park, NC; 4North Broward Hosp. District, Ft. Lauderdale, FL; and 5Louis Stokes VA Med. Ctr., Cleveland, OH
| ||
| 702-T. | A Randomized, Double-Blind, Placebo-Controlled, Comparative Study on the Effects of Metformin or Gemfibrozil in Lipodystrophic HIV-1-Infected Patients Receiving Protease Inhibitors (PI) E. Martínez*, P. Domingo, J. B. Pérez-Cuevas, J. A. Arroyo, E. Buira, A. Milinkovic, I. Conget, J. Mallolas, G. Vázquez, and J. M. Gatell Hosp. Clin. and Hosp. de Sant Pau, Barcelona, Spain
| ||
| 703-T. | Effects of Niacin upon Fat Expansion in HIV-Positive Patients Who Have the Fat Redistribution Syndrome (FRS) J. Fessel* and S. Follansbee Kaiser Permanente Med. Care Prog., San Francisco, CA
| ||
| 704-T. | Treatment of HIV-Associated Lipoatrophy of the Face with Intradermal Injections of Polylactic Acid M. Lafaurie*, J. Dolivo, D. Boulu, I. Madelaine, and J. M. Molina St. Louis Hosp., Paris, France
| ||
| 705-T. | Randomized Phase III Trial of Oxymetholone for the Treatment of HIV Wasting and Lipodystrophy U. R. Hengge*1, K. Stocks1, S. Unger1, S. Faulkner2, M. Goos1, and R. Dudley2 1Univ. of Essen, Germany and 2Unimed Pharmaceuticals, Inc., Deerfield, IL
| ||
| 706-T. | Atazanavir: A Once-Daily Protease Inhibitor with a Superior Lipid Profile: Results of Clinical Trials Beyond Week 48 P. Piliero*1, P. Cahn2, G. Pantaleo3, J. M. Gatell4, K. Squires5, L. Percival6, I. Sanne7, R. Wood8, P. Phanuphak9, S. Shelton10, A. Lazzarin11, A. Thiry6, T. Kelleher6, M. Giordano6, and S. M. Schnittman6 1Albany Med Coll., NY; 2Fndn. Hosp., Buenos Aires, Argentina; 3Centre Hosp. Univ. Vaudois, Lausanne, Switzerland; 4Hosp. Clin Provencial de Barcelona, Spain; 5Rand Schrader Clin. and LAC and USC Med. Ctr., Los Angeles, CA; 6Bristol-Myers Squibb, Wallingford, CT; 7WHC Infectious Disease Clin. Trials Unit, Johannesburg, South Africa; 8Univ. of Capetown, South Africa; 9Chulalongkorn Univ., Bangkok, Thailand; 10Bristol-Myers Squibb, Waterloo, Belgium; and 11S. Raffaele Hosp., Milan, Italy
|
